SAN DIEGO–(BUSINESS WIRE)–BioDuro, LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic.
The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics experience. The new service offerings, focused on antibody discovery and cellular therapies, include:
- Single B cell and next-generation animal-based Ab discovery. Increase efficiency of clone retrieval, resulting in higher quality antibody ‘hits’ in less time.
- AI powered synthetic Ab technology. Achieve higher efficiency, better developability and overcome the limitation of animal immune systems compared to traditional methods.
- Immune cell therapies. Design, construct and optimize immune cell (e.g. CAR-T) therapies for superior efficacy, safety, and low side effects.
“Antibody- and cell-based therapies are providing some of the most exciting advances in medicine, including unprecedented progress in immune-oncology,” said Xiang Li, DPhil, Senior Vice President, Integrated Biology at BioDuro. “We have carefully developed and validated our biologics discovery services for several years prior to launch. In fact, our early partners have already taken a number of programs we have worked on into the clinic.”
The new biologics service offering adds to a comprehensive set of existing BioDuro capabilities, including chemistry, biology, DMPK, pharmacology, toxicology, formulation and GMP manufacturing of drug products. The combined capabilities provide BioDuro partners with a fully integrated drug discovery, development and manufacturing provider for both new chemical entity (NCE) and new biological entity (NBE) based medicines.
BioDuro is a leading, global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery services spanning target identification to IND filing, through to GMP manufacture of drug substance for clinical trials. With depth and breadth of therapeutic expertise in small and large molecule discovery, development and scale up, combined with unique technology platforms such as high content 3D drug screening and bioavailability enhancement of insoluble compounds, BioDuro is well positioned to help biopharmaceutical partners significantly accelerate their lead discovery programs, and de-risk development programs for higher value outcomes. Visit www.bioduro.com